Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL25282587 | 0.95 | CCR6 (0.55) | CCR6PAX8ALDH1A1TDP1MAPK1 | |
| SCHEMBL18057682 | 0.94 | CCR6 (0.60) | CCR6PAX8ALDH1A1TDP1MAPK1 | |
| SCHEMBL13661129 | 0.94 | CCR6 (0.57) | CCR6PAX8ALDH1A1TDP1MAPK1 | |
| SCHEMBL18594775 | 0.93 | CCR6 (0.52) | CCR6PAX8ALDH1A1TDP1MAPK1 | |
| SCHEMBL15508590 | 0.92 | CCR6 (0.63) | CCR6PAX8ALDH1A1TDP1MAPK1 | |
| SCHEMBL8900957 | 0.92 | CCR6 (0.51) | CCR6PAX8ALDH1A1TDP1MAPK1 | |
| SCHEMBL17275425 | 0.91 | CCR6 (0.61) | CCR6PAX8ALDH1A1TDP1MAPK1 | |
| SCHEMBL18057683 | 0.91 | CCR6 (0.61) | CCR6PAX8ALDH1A1TDP1MAPK1 | |
| SCHEMBL13049197 | 0.91 | CCR6 (0.50) | CCR6PAX8ALDH1A1TDP1MAPK1 | |
| SCHEMBL14476880 | 0.90 | CCR6 (0.63) | CCR6PAX8ALDH1A1TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353805-A1 | PROCESS | GIVAUDAN SA (CH) | 2025-11-20 | — | — | US | disclosed |
| EP-4452914-A1 | PROCESS | Givaudan SA (CH) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118051-A1 | PROCESS | GIVAUDAN SA (CH) | 2023-06-29 | — | — | WO | disclosed |
| US-11666625-B2 | Pharmaceutical compositions and preparations for administration to the eye | Allegro Pharmaceuticals, LLC (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20130005674-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8114856-B2 | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents | ISIS PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110166334-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS,INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-7795166-B2 | Functional group-selective hydrogenation catalyst and functional group-selective hydrogenation method | N.E. CHEMCAT CORPORATION (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070155617-A1 | FUNCTIONAL GROUP-SELECTIVE HYDROGENATION CATALYST AND FUNCTIONAL GROUP-SELECTIVE HYDROGENATION METHOD | N. E. CHEMCAT CORPORATION (JP) | 2007-07-05 | — | — | US | disclosed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166334-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | CCR6 3285/4885PAX8 4700/4885ALDH1A1 2097/4885 |
| US-20130005674-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | CCR6 3285/4885PAX8 4700/4885ALDH1A1 2097/4885 |
| US-11666625-B2 | Pharmaceutical compositions and preparations for administration to the eye | GCG, HGFAC, ARGLU1 | CCR6 51/4885PAX8 3345/4885ALDH1A1 2782/4885 |
| US-20250353805-A1 | PROCESS | DEGS1, FDFT1, SQLE | CCR6 3793/4885PAX8 2982/4885ALDH1A1 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.